Q2 2020 13F Holders as of 30 Jun 2020
-
Type / Class
-
Equity / Common Stock, par value $0.00001 per share
-
Shares outstanding
-
108,380,780
-
Total 13F shares
-
28,456,883
-
Share change
-
-3,663,878
-
Total reported value
-
$46,099,261
-
Price per share
-
$1.62
-
Number of holders
-
56
-
Value change
-
-$5,512,533
-
Number of buys
-
20
-
Number of sells
-
41
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) as of Q2 2020
As of 30 Jun 2020 Aclaris Therapeutics, Inc. - Common Stock, par value $0.00001 per share (ACRS) had 56 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 28,456,883 shares of stock of the company.
Largest 10 holders included MFN Partners Management, LP, RENAISSANCE TECHNOLOGIES LLC, Samsara BioCapital, LLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Sofinnova Investments, Inc., Endurant Capital Management LP, Parkman Healthcare Partners LLC, Vivo Capital, LLC, Rock Springs Capital Management LP, and EcoR1 Capital, LLC.
This table shows 56 institutional shareholders of the security as of 30 Jun 2020.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.